131468-33-2

Usage

Uses

Used in Pharmaceutical Industry:
4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine is utilized as a component in the production of pesticides and other agrochemicals, leveraging its chemical properties to enhance crop protection and yield.
Used in Dye Industry:
4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine is also employed in the dye industry, where it serves as a key intermediate in the creation of various dyes, contributing to the colorfastness and vibrancy of textiles and other materials.
Used in Organic Synthesis:
4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine is used as a versatile building block in organic synthesis, enabling the construction of a wide array of complex organic compounds for diverse applications across different industries.
It is crucial to handle 4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine with care due to its potential risks to human health and the environment if mismanaged. Proper safety measures and disposal methods should be strictly adhered to in its use and production processes.

InChI:InChI=1/C9H5Cl2FN4/c10-7-14-8(11)16-9(15-7)13-6-3-1-5(12)2-4-6/h1-4H,(H,13,14,15,16)

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 924892-76-2 6-chloro-N-(4-fluorophenyl)-N'-(4-trifluoromethoxyphenyl)-1,3,5-triazine-2,4-diamine 
• 924892-75-1 6-chloro-N-(4-fluorophenyl)-N'-(4-methoxyphenyl)-1,3,5-triazine-2,4-diamine 
• 924892-68-2 N-benzyl-6-chloro-N'-(4-fluorophenyl)-1,3,5-triazine-2,4-diamine 
• 1075732-31-8 C₂₇H₃₇FN₈O₄S 
• 1075732-28-3 C₁₇H₁₅ClFN₅O 

Relevant academic research and scientific papers

Synthesis and characterization of new s-triazine bearing benzimidazole and benzothiazole derivatives as anticancer agents

Two new series of s-triazine derivatives appended with benzimidazole (15a-h) and benzothiazole derivatives (16a-h) are synthesized, and structure-activity relationships on anticancer activity of these 15a-h and 16a-h were probed. In vitro inhibitory activity against the growth of six cancer cell lines, viz., MCF-7, MDAMB-231, PC-3, DU-145, HT-29 and HGC-27 was evaluated for synthesized analogues. Among the two series of compounds, derivatives containing benzimidazole scaffold were found to be relatively potent over benzothiazole analogues. In accordance with our previous observation, within benzimidazole derivatives, tri-substituted s-triazine derivatives were found to be more potent over di-substituted derivatives irrespective of cell lines. Structure-activity relationships provided useful insights into these classes of compounds and paved the way to design novel analogues with more potency.

Synthesis and anticancer activity of some new s-triazine derivatives

New s-triazine derivatives 13a-h were synthesized for the structure-activity relationship studies as potent anticancer agents. The prepared analogues were evaluated for their in vitro inhibitory activity against the growth of PA-1 (Ovarian cancer), A549 (Lung cancer), MCF-7 (Breast cancer), and HT-29 (Colon cancer). Tri-substituted s-triazine derivatives (13e-h) with morpholino group on s-triazine scaffold exhibited potent anticancer activities compared to di-substituted s-triazine derivatives. Compounds 13e-h also showed relatively selective PA-1 and HT-29 cancer cell inhibition over other cancer cell lines. Structure-activity relationships provided useful insights in these classes of compounds and paved the way to design novel analogues with more potency.

Triazine-benzimidazole conjugates: Synthesis, spectroscopic and molecular modelling studies for interaction with calf thymus DNA

Triazine-benzimidazole analogues with different substitutions of primary and secondary amines as well as aryl groups were synthesized and characterized by 1H, 13C NMR and mass spectrometry. Interactions of these compounds with ct-DNA were explored by spectroscopic and viscometric techniques. These results and molecular modelling studies showed that compounds 7, 9-11, 16 and 21 interacted with ct-DNA through groove binding and not intercalation.

Discovery of Small-Molecule Cyclic GMP-AMP Synthase Inhibitors

Cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) (cGAS), a cytosolic DNA sensor, plays an important role in the type I interferon response. DNA from either invading microbes or self-origin triggers the enzymatic activity of cGAS. Aberrant activation of cGAS is associated with various autoimmune disorders. Only one selective probe exists for inhibiting cGAS in cells, while others are limited by their poor cellular activity or specificity, which underscores the urgency for discovering new cGAS inhibitors. Here, we describe the development of new small-molecule human cGAS (hcGAS) inhibitors (80 compounds synthesized) with high binding affinity in vitro and cellular activity. Our studies show CU-32 and CU-76 selectively inhibit the DNA pathway in human cells but have no effect on the RIG-I-MAVS or Toll-like receptor pathways. CU-32 and CU-76 represent a new class of hcGAS inhibitors with activity in cells and provide a new chemical scaffold for designing probes to study cGAS function and development of autoimmune therapeutics.

PIKFYVE INHIBITORS

The present application provides, inter alia, a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, a

Design and development of novel thiazolidin-4-one-1,3,5-triazine derivatives as neuro-protective agent against cerebral ischemia–reperfusion injury in mice via attenuation of NF-?B

The present study enumerates the discovery and development of novel thiazolidin-4-one-1,3,5-triazine as neuro-protective agent against cerebral ischemia–reperfusion injury in mice. These compounds showed significant inhibition of NF-?B transcriptional activity in LPS-stimulated RAW264.7 cells, displaying compound 8k as most potent inhibitor among the tested derivative. The compound 8k was further studied in in vivo middle cerebral artery occlusion (MCAO) mice model for neuro-protective action. Results suggest that compound 8k causes attenuation of inflammation (TNF-α, IL-β, and IL-6), oxidative stress (SOD, GSH, and MDA), and apoptosis (Bcl-2, Bax, and cleaved caspase-3) in MCAO mice in concentration-dependent manner. Collectively, our results documented that compound 8k pre-treatment protects cerebral I/R. This novel lead scaffold may be helpful for investigation of new neuro-protective agent by inactivation of NF-?B.

NOVEL CYCLIC GMP-AMP SYNTHASE (CGAS) INHIBITORS AND THEIR METHOD OF USE

Methods of treating diseases related to cGAS activation. Small molecule inhibitors of cGAS and pharmaceutical compositions and uses thereof in treating autoimmune diseases or inflammation.

Heterocyclic compounds as well as preparation method and application thereof

The invention belongs to the field of medicines and particularly relates to heterocyclic compounds with the structural characteristics shown in formula (I) or pharmaceutically acceptable salts, a preparation method and an application of the heterocyclic compounds as a nucleotide oxidative damage repairase MTH1 inhibitor. Pharmacological experiment results indicate that the compounds have significant inhabitation effects on the activity of MTH1 and can be used for preventing and treating clinical diseases related to MTH1.

Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation

Low-molecular-weight synthetic molecules 1 with the general 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activities were explored. Structure–activity relationship studies demonstrated the importance of the aminopentyl chain, the 3- or 4-fluorophenylaniline component, and the presence of at least one substituent, such as a tyramine moiety, attached directly to the triazine ring as essential for good activity. These compounds, represented by leads 4-{2-[4-(5-Aminopentylamino)-6-(3-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (6) and 4-{2-[4-(5-Aminopentylamino)-6-(4-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (10), displayed moderate and significant in vitro and in vivo dual activities, respectively, and address the molecular link between inflammation and cancer. Compound 10 demonstrated significant antitumor efficacy upon administration by the oral and intravenous routes in several animal models. This class of triazine compounds is new, safe, and nontoxic and offers a novel approach to the treatment of inflammation and cancer.

Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives

Human African trypanosomiasis is causing thousands of deaths every year in the rural areas of sub-saharan Africa. There is a high unmet medical need since the approved drugs are poorly efficacious, show considerable toxicity and are not easy to administer